title: March-in rights under the Bayh-Dole Act: the NIH's paper tiger?
authors.forename: William
authors.initials: W
authors.lastname: O'Brien
mesh_terms: D004345:Drug Industry / Q000331:legislation & jurisprudence*; D056947:Enzyme Replacement Therapy; D000795:Fabry Disease / Q000628:therapy; D005380:Financing, Government / Q000266:history / Q000331:legislation & jurisprudence*; D018166:Health Care Reform / Q000331:legislation & jurisprudence; D049673:History, 20th Century; D006801:Humans; D018973:Intellectual Property; D009316:National Institutes of Health (U.S.); D010330:Patents as Topic / Q000266:history / Q000331:legislation & jurisprudence*; D012109:Research Support as Topic / Q000266:history / Q000331:legislation & jurisprudence; D014481:United States; D000519:alpha-Galactosidase / Q000235:genetics / Q000627:therapeutic use
chemical_list: D000519:alpha-Galactosidase